Association between high Gal-3 serum levels and worsening of renal function in chronic heart failure outpatients

Papers of special note have been highlighted as: • of interest

References

• 1. Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64(1), 1–12 (2004).
  Medline CASGoogle Scholar
• 2. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19), 3121–3128 (2004).
  Medline CASGoogle Scholar
• 3. Vergaro G, Del Franco A, Giannoni A et al. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int. J. Cardiol. 184, 96–100 (2015).
  MedlineGoogle Scholar
• 4. de Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43(1), 60–68 (2015).
  Google Scholar
• 5. McEvoy JW, Chen Y, Halushka MK et al. Galectin-3 and risk of heart failure and death in blacks and whites. J. Am. Heart Assoc. 5(5), e003079 (2016).
  MedlineGoogle Scholar
• 6. Grande D, Leone M, Rizzo C et al. A multiparametric approach based on NT-proBNP, ST2, and galectin-3 for stratifying one year prognosis of chronic heart failure outpatients. J. Cardiovasc. Dev. Dis. 4(3), E0009 (2017).
  MedlineGoogle Scholar
• 7. Henderson NC, MacKinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172(2), 288–298 (2008). • Galectin-3 is upregulated in a mouse model of progressive renal fibrosis.
  Medline CASGoogle Scholar
• 8. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J. Am. Soc. Nephrol. 24(9), 1470–1477 (2013). • In Framingham Offspring participants high Gal-3 levels were associated with increased risks of rapid glomerular filtration rate decline.
  MedlineGoogle Scholar
• 9. Rebholz CM, Selvin E, Liang M et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 93(1), 252–259 (2018).
  Medline CASGoogle Scholar
• 10. Gopal DM, Kommineni M, Ayalon N et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J. Am. Heart Assoc. 1(3), e000760 (2012).
  MedlineGoogle Scholar
• 11. Iacoviello M, Aspromonte N, Leone M et al. Galectin-3 serum levels are independently associated with microalbuminuria in chronic heart failure outpatients. Res. Cardiovasc. Med. 5(1), e28952 (2015).
  MedlineGoogle Scholar
• 12. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18(8), 891–975 (2016).
  MedlineGoogle Scholar
• 13. Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr. 23(7), 685–713 (2010).
  MedlineGoogle Scholar
• 14. Levey AS, LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).
  MedlineGoogle Scholar
• 15. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 49(2), S12–S154 (2007).
  MedlineGoogle Scholar
• 16. Damman K, Tang WH, Testani JM, McMurray JJ. Terminology and definition of changes renal function in heart failure. Eur. Heart J. 35(48), 3413–3416 (2014).
  Medline CASGoogle Scholar
• 17. Laird N, Ware J. Random-effects models for longitudinal data. Biometrics 38(4), 963–974 (1982).
  Medline CASGoogle Scholar
• 18. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102(2), 203–210 (2000).
  Medline CASGoogle Scholar
• 19. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. Current and novel renal biomarkers in heart failure. Heart Fail. Rev. 17(2), 241–250 (2012).
  MedlineGoogle Scholar
• 20. Damman K, Kalra PR, Hillege H. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure. J. Ren. Care 36(1), 18–26 (2010).
  MedlineGoogle Scholar
• 21. Tang WH, Shrestha K, Shao Z et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 108(3), 385–390 (2011).
  Medline CASGoogle Scholar
• 22. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulias P, Butler J, Giamouzis G. The emerging role of galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr. Heart Fail. Rep. 10(4), 441–449 (2013). • Highlights practical aspects for the use of Gal-3 and ST-2 in heart failure.
  Medline CASGoogle Scholar